candesartan has been researched along with Thrombosis in 3 studies
candesartan: a nonpeptide angiotensin II receptor antagonist
candesartan : A benzimidazolecarboxylic acid that is 1H-benzimidazole-7-carboxylic acid substituted by an ethoxy group at position 2 and a ({2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl}methyl) group at position 1. It is a angiotensin receptor antagonist used for the treatment of hypertension.
Thrombosis: Formation and development of a thrombus or blood clot in the blood vessel.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Losartan is a non-peptidic inhibitor of AT1 receptors." | 2.41 | Angiotensin II AT(1) receptor antagonists and platelet activation. ( Casado, S; Gómez, J; Jiménez, A; Lopez-Bloya, A; López-Farré, A; Montón, M; Núñez, A; Rico, L; Sánchez de Miguel, L, 2001) |
| "Pathogenic thrombus formation accounts for the etiology of many serious conditions including myocardial infarction, stroke, deep vein thrombosis, and pulmonary embolism." | 1.56 | Progress toward a Glycoprotein VI Modulator for the Treatment of Thrombosis. ( Foster, H; Foster, R; Philippou, H; Wilson, C, 2020) |
| "Candesartan has a preventive value against atherosclerotic plaque rupture in hypercholesterolemic rabbits, likely through its reduction of MMP-9 expression, inhibition of macrophage accumulation and increase of collagen content within the plaques." | 1.36 | [Prevention of rupture of atherosclerotic plaque by Candesartan in rabbit model]. ( Li, SA; Meng, ZM; Qian, HD; Shen, L; Wu, AS; Yin, HC; Yu, T; Zhou, XF; Zhu, WL, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Foster, H | 1 |
| Wilson, C | 1 |
| Philippou, H | 1 |
| Foster, R | 1 |
| Zhou, XF | 1 |
| Yin, HC | 1 |
| Zhu, WL | 1 |
| Shen, L | 1 |
| Yu, T | 1 |
| Li, SA | 1 |
| Meng, ZM | 1 |
| Wu, AS | 1 |
| Qian, HD | 1 |
| López-Farré, A | 1 |
| Sánchez de Miguel, L | 1 |
| Montón, M | 1 |
| Jiménez, A | 1 |
| Lopez-Bloya, A | 1 |
| Gómez, J | 1 |
| Núñez, A | 1 |
| Rico, L | 1 |
| Casado, S | 1 |
1 review available for candesartan and Thrombosis
| Article | Year |
|---|---|
Angiotensin II AT(1) receptor antagonists and platelet activation.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Angiotensin Receptor Antagonists | 2001 |
2 other studies available for candesartan and Thrombosis
| Article | Year |
|---|---|
Progress toward a Glycoprotein VI Modulator for the Treatment of Thrombosis.
Topics: Binding Sites; Biological Products; Humans; Ligands; Losartan; Molecular Dynamics Simulation; Platel | 2020 |
[Prevention of rupture of atherosclerotic plaque by Candesartan in rabbit model].
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Aorta, Abdominal; Benzimi | 2010 |